Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model

Figure 8

Subchronic treatment with fenofibrate (F), metformin (M), and their combination increases GTPCH-I expression and BH₄ : BH₂ ratio in both control- (CT-) and diabetic- (DB-) rats subjected to ischemia/reperfusion (I/R). GTPCH-I expression was evaluated in ischemic left ventricle area from CT- and DB-rats subjected to sham- (SH-) or I/R-myocardial infarction and treated subchronically (14 d) with either vehicle, fenofibrate (F, 100 mg/kg), metformin (M, 100 or 300 mg/kg), or Feno (50 mg/kg) + Metfor (50 mg/kg). (a) Representative immunoblot and GTPCH-I expression ( rats/group) and (b) BH₄ : BH₂ ratio (–6 rats/group). versus CTSH-Vehicle, versus CTI/R-Vehicle, and versus DBI/R-Vehicle two-way ANOVA followed by Duncan’s post hoc test. Data are presented as means ± SEM.

(a)

(b)